CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease.
Aged
Aged, 80 and over
Alzheimer Disease
/ genetics
Apolipoprotein E4
/ genetics
Biomarkers
/ blood
Chemokines, CC
/ blood
Cognitive Dysfunction
/ genetics
Cross-Sectional Studies
Disease Progression
Early Diagnosis
Female
Genotype
Humans
Kaplan-Meier Estimate
Longitudinal Studies
Male
Mental Status and Dementia Tests
Middle Aged
Predictive Value of Tests
Alzheimer’s disease
biomarkers
chemokines
cognitive dysfunction
early diagnosis
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2020
2020
Historique:
pubmed:
21
1
2020
medline:
7
5
2021
entrez:
21
1
2020
Statut:
ppublish
Résumé
CCL23 is a chemokine implicated in inflammation and host defense responses. It has been recently associated with acquired brain damage and stroke outcomes. In this study, we reported the role of CCL23 in Alzheimer's disease (AD). We evaluated the levels of CCL23 in 659 individuals: cognitively normal, mild cognitive impaired (MCI), and AD patients. Two cross-sectional (study 1, n = 53; study 2, n = 200) and two longitudinal (study 3, n = 74; study 4, n = 332) studies were analyzed separately. CCL23 levels in the blood and/or cerebrospinal fluid (CSF) of each study were measured by immunoassays. Globally, our results suggest a predictive role of CCL23 protein levels both in the plasma in study 3 (hazard ratio (HR) = 2.5 (confidence interval (CI) 95% : 1.2-5.3), p = 0.02) and in the CSF in study 4 (HR = 3.05 (CI 95% : 1.02-5), p = 0.04) in cases of MCI that progress to AD. Moreover, we observed that the APOEɛ4 allele was associated with higher levels of CCL23 in study 2 (470.33 pg/mL (interquartile range (IQR): 303.33-597.76) versus 377.94 pg/mL (IQR: 267.16-529.19), p = 0.01) (APOE genotypes were available in studies 2 and 4). Together, these findings support the role of CCL23 in neuroinflammation in the early stages of AD, suggesting that CCL23 might be a candidate blood biomarker for MCI to AD progression.
Identifiants
pubmed: 31958084
pii: JAD190753
doi: 10.3233/JAD-190753
pmc: PMC8010612
mid: NIHMS1682844
doi:
Substances chimiques
Apolipoprotein E4
0
Biomarkers
0
CCL23 protein, human
0
Chemokines, CC
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1585-1595Subventions
Organisme : NIA NIH HHS
ID : P30 AG066444
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG064877
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG057777
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG053303
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG058922
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG044546
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG003991
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005681
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG026276
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG058501
Pays : United States
Références
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Biol Psychiatry. 2010 Nov 15;68(10):903-12
pubmed: 21035623
Neurology. 2015 Aug 18;85(7):626-33
pubmed: 26180139
Annu Rev Neurosci. 2014;37:79-100
pubmed: 24821312
Neuromolecular Med. 2016 Mar;18(1):99-108
pubmed: 26661731
PLoS Genet. 2014 Oct 23;10(10):e1004758
pubmed: 25340798
Biomark Med. 2012 Aug;6(4):441-54
pubmed: 22917146
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Exp Hematol. 2005 Oct;33(10):1101-8
pubmed: 16219532
Nat Rev Neurol. 2015 Jan;11(1):41-55
pubmed: 25511894
Nat Rev Neurosci. 2015 Jun;16(6):358-72
pubmed: 25991443
Arch Neurol. 2012 Oct;69(10):1318-25
pubmed: 22801742
BMC Neurol. 2011 May 12;11:51
pubmed: 21569380
Neurotherapeutics. 2007 Oct;4(4):590-601
pubmed: 17920540
J Psychiatr Res. 2014 Jun;53:166-72
pubmed: 24576746
JAMA Neurol. 2019 Jul 1;76(7):791-799
pubmed: 31009028
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Ann Neurol. 2003 Nov;54(5):638-46
pubmed: 14595653
J Exp Med. 1997 Apr 7;185(7):1163-72
pubmed: 9104803
Exp Gerontol. 2007 Mar;42(3):233-40
pubmed: 17085001
J Neurol Neurosurg Psychiatry. 2017 Oct;88(10):876-882
pubmed: 28794151
J Intern Med. 2018 May;283(5):461-475
pubmed: 29415332
Arch Dermatol Res. 2011 Jan;303(1):29-34
pubmed: 20824279
Science. 1993 Aug 13;261(5123):921-3
pubmed: 8346443
Am J Alzheimers Dis Other Demen. 2016 May;31(3):194-200
pubmed: 26340961
PLoS One. 2013 Jun 10;8(6):e64971
pubmed: 23762274
Neurology. 2012 Aug 28;79(9):897-905
pubmed: 22855860
Biol Psychiatry. 2014 May 1;75(9):723-31
pubmed: 24548642
Mol Diagn Ther. 2017 Feb;21(1):13-22
pubmed: 27738910
Alzheimers Dement. 2014 Jan;10(1):115-31
pubmed: 23850333
Arthritis Rheum. 2008 Aug;58(8):2257-67
pubmed: 18668547
Curr Opin Neurobiol. 2011 Dec;21(6):920-8
pubmed: 21907569
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
Arch Neurol. 2012 Jun;69(6):757-64
pubmed: 22689192
Am J Alzheimers Dis Other Demen. 2014 Aug;29(5):415-25
pubmed: 24408754
Life Sci. 2010 Feb 27;86(9-10):300-8
pubmed: 19951712
Lancet. 2016 Jul 30;388(10043):505-17
pubmed: 26921134
Alzheimers Dement. 2015 May;11(5):523-32
pubmed: 25156643
Neurology. 2017 Jul 11;89(2):178-188
pubmed: 28592456
Mol Neurodegener. 2013 Jun 21;8:20
pubmed: 23800368
Arch Neurol. 2006 Apr;63(4):538-43
pubmed: 16606766
Blood. 1998 May 1;91(9):3118-26
pubmed: 9558365